Offering multiple preclinical metastatic models to fit multiple metastasis questions
For most cancer patients, a primary, solid tumor can be easily treated with surgery. Many of these patients will eventually die of cancer but as a result of refractory reoccurrence and metastasis. For this reason, metastatic models remain an essential part of the oncology toolkit.
Oncodesign Services offers a range of metastasis models that vary by injection site, which address certain parts of the complex metastatic cascade, from generation of circulating tumor cells (CTCs) to tumor growth at a distal site.
The tumor burden and dissemination of metastatic tumors can be monitored using ex vivo examination of organs or in vivo imaging such as MRI, PET, PET/MRI, SPECT and optical imaging.
Summary of available metastasic models
| Metastasis Site | Model | Injection Site | Also to Lymph | Tumor type | Incidence | SOC |
| Liver | CT-26 colon
LS174T colon HCT-116 colon CR-LRB-018P colon MP55 melanoma IM-PAN-010 pancreas |
IV
Intrasplenic OT OT Caecum OT Choroid SC |
Syngeneic
CDX CDX PDX PDX PDX |
100%
60-80% 90% 100% 33% 40% |
CPT-11
CPT-11 |
|
| Lung | 4T1 breast
Rena kidney B16-F10 melanoma B16-F10 melanoma MDA-MB-231 breast OD-BRE-0192 breast IM-PAN-015 |
OT, MFP
OT IV Intradermal IV OT, MFP SC |
Yes | Syngeneic
Syngeneic Syngeneic Syngeneic CDX PDX PDX |
100%
100% 100% 80-90% 66% 30% 40-60% |
Doxorubicin, indomethacin
Sunitinib, Sorafenib Cyclophosphamide Paclitaxel |
| Brain | B16-F10 melanoma
BT-474 breast A-549 lung NCI-H460 lung CMEL-5 melanoma |
Intracranial
Intracranial Intracranial Intracranial IV |
Yes | Syngeneic
CDX CDX CDX CDX |
100%
100% 100% 100% 100% |
Temozolomide
Paclitaxel, CDDP, TMZ, Gemcitbine Paclitaxel |
| Spleen | CT-26 colon | caecum | Syngeneic | 30-40% | ||
| Bone | CMEL-5 melanoma
CMEL5 melanoma PC-3 prostate Proprietary prostate |
IV
OT Intracardiac Intratibial |
Yes
Yes Yes |
CDX
CDX CDX CDX |
100%
100% 69% 100% |
Temozolomide
Paclitaxel |
CASE STUDY #1
The B16-F10 mouse melanoma model was implanted intravenously in C57b6 mice, with lung tumor colonies measured after termination. Cyclophosphamide successfully repressed most of the lung mets forming.
